BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26164385)

  • 1. Inclusion bodies of recombinant Epstein-Barr virus capsid antigen p18 as potential immobilized antigens in enzyme immunoassays for detection of nasopharyngeal carcinoma.
    Lim CS; Goh SL; Kariapper L; Krishnan G; Lim YY; Ng CC
    Clin Chim Acta; 2015 Aug; 448():206-10. PubMed ID: 26164385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease.
    Fachiroh J; Stevens SJ; Haryana SM; Middeldorp JM
    J Virol Methods; 2010 Oct; 169(1):79-86. PubMed ID: 20621126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
    Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
    Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
    Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serological diagnosis of Epstein-Barr virus infection by novel ELISAs based on recombinant capsid antigens p23 and p18.
    Färber I; Hinderer W; Rothe M; Lang D; Sonneborn HH; Wutzler P
    J Med Virol; 2001 Apr; 63(4):271-6. PubMed ID: 11241457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
    Li RC; Du Y; Zeng QY; Tang LQ; Zhang H; Li Y; Liu WL; Zhong Q; Zeng MS; Huang XM
    Oncotarget; 2016 Mar; 7(13):16372-83. PubMed ID: 27093005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein.
    van Grunsven WM; Spaan WJ; Middeldorp JM
    J Infect Dis; 1994 Jul; 170(1):13-9. PubMed ID: 8014488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.
    Peng YH; Xu YW; Huang LS; Zhai TT; Dai LH; Qiu SQ; Yang YS; Chen WZ; Zhang LQ; Li EM; Xu LY
    Cancer Prev Res (Phila); 2015 Aug; 8(8):729-36. PubMed ID: 25990085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma.
    Zhang C; Zong Y; Huang B; Sun Y; Ye Y; Feng K; Li J; Zhang F
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):356-9. PubMed ID: 12408763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
    J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening.
    Fachiroh J; Prasetyanti PR; Paramita DK; Prasetyawati AT; Anggrahini DW; Haryana SM; Middeldorp JM
    J Clin Microbiol; 2008 Apr; 46(4):1374-80. PubMed ID: 18256216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis.
    Li S; Deng Y; Li X; Chen QP; Liao XC; Qin X
    Chin Med J (Engl); 2010 May; 123(9):1201-5. PubMed ID: 20529563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnosis of nasopharyngeal carcinoma in China: a case-control trial.
    Gao R; Wang L; Liu Q; Zhang LF; Ye YF; Xie SH; Du JL; Chen SH; Guo J; Yang MJ; Lin CY; Cao SM
    BMJ Open; 2017 Jul; 7(6):e013211. PubMed ID: 28674124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparison of the detection of IgM antibodies against the viral capsid antigen (VCA) of EBV (Epstein-Barr virus) in various groups of patients, using indirect immunofluorescence, indirect ELISA and reverse ELISA. Study of the diagnostic efficacy of the anti-VCA EBV IgM ELISA-VIDITEST kit].
    Pumannová M; Rezbová M; Svecová M; Hrbácková H; Novotná M; Ochotná J; Roubalová K
    Klin Mikrobiol Infekc Lek; 2004 Aug; 10(4):186-90. PubMed ID: 15328576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.